Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT06538116
- Locations
- 🇺🇸
Banner Alzheimer's Institute, Phoenix, Arizona, United States
🇺🇸Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States
🇺🇸Profound Research, LLC, Carlsbad, California, United States
A Study of Subcutaneous Injection in Healthy Participants
- Conditions
- Healthy
- Interventions
- Device: Syringe Pump
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT06516913
- Locations
- 🇺🇸
Fortrea CRU, Inc., Dallas, Texas, United States
A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 484
- Registration Number
- NCT06475729
- Locations
- 🇺🇸
CenExel ACT, Anaheim, California, United States
🇺🇸Fortrea Clinical Research Unit, Madison, Wisconsin, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Conditions
- Metastatic Solid TumorRecurrent Solid TumorAdvanced Solid TumorUrinary Bladder NeoplasmTriple Negative Breast CancerNon-small Cell Lung CancerEsophageal CancerPancreatic CancerOvarian CancerCervical Cancer
- Interventions
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 420
- Registration Number
- NCT06465069
- Locations
- 🇺🇸
Sarah Cannon Research Institute at HealthOne, Denver, Colorado, United States
🇺🇸Florida Cancer Specialists and Research Institute, Saint Petersburg, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis
- First Posted Date
- 2024-06-05
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 55
- Registration Number
- NCT06444165
- Locations
- 🇺🇸
Concentrics Research, Indianapolis, Indiana, United States
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 533
- Registration Number
- NCT06440980
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Collaborative Neuroscience Research, LLC, Los Alamitos, California, United States
🇺🇸Fortrea Clinical Research Unit, Madison, Wisconsin, United States
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 300
- Registration Number
- NCT06439277
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Sutter Valley Medical Foundation (SVMF) Pediatric Endocrinology, Sacramento, California, United States
🇺🇸Nemours Children's Health - Delaware, Wilmington, Delaware, United States
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 45
- Registration Number
- NCT06413706
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
- Conditions
- Ovarian NeoplasmsEndometrial NeoplasmsColorectal NeoplasmsUterine Cervical NeoplasmsPancreatic NeoplasmCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms
- Interventions
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 360
- Registration Number
- NCT06400472
- Locations
- 🇪🇸
Hospital Clinico Universitario de Valencia, Valencia, Spain
🇺🇸Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸South Texas Accelerated Research Therapeutics (START), Grand Rapids, Michigan, United States
A First-In-Human Study of LY3985297 in Healthy Participants
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 153
- Registration Number
- NCT06395012
- Locations
- 🇺🇸
CenExel ACT, Anaheim, California, United States
🇺🇸ICON, Salt Lake City, Utah, United States